Literature DB >> 2651586

The treatment of spontaneous intracerebral hemorrhage. A prospective randomized trial of surgical and conservative treatment.

S Juvela1, O Heiskanen, A Poranen, S Valtonen, T Kuurne, M Kaste, H Troupp.   

Abstract

In a prospective study, 52 patients with a spontaneous supratentorial intracerebral hematoma (ICH) were randomly assigned to receive emergency surgery or conservative treatment within 48 hours after the bleed. Patients with a decreased level of consciousness and/or a severe neurological deficit were admitted to the study. The overall mortality rate at 6 months was 42%: 10 (38%) of the 26 patients in the conservative group and 12 (46%) of the 26 in the surgical group. Six (20%) of the 30 survivors at 6 months were able to conduct their activities of daily living independently: five (31%) of the 16 patients in the conservative group and one (7%) of the 14 in the operative group. These differences are not statistically significant. The mortality rate of semicomatose or stuporous patients (Glasgow Coma Scale score 7 to 10) was statistically significantly lower in the surgical group (none of the four patients) than in the conservative group (four of five patients) (p less than 0.05); however, all surviving patients in this subgroup were severely disabled. The study suggests that surgical treatment of this category of patients with ICH does not offer any definite advantage over conservative treatment. In semicomatose or stuporous patients, surgery may improve the length of survival, but the quality of life remains poor.

Entities:  

Mesh:

Year:  1989        PMID: 2651586     DOI: 10.3171/jns.1989.70.5.0755

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  63 in total

1.  Intracerebral Hemorrhage.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-05       Impact factor: 3.598

Review 2.  Services for people with stroke.

Authors:  D T Wade
Journal:  Qual Health Care       Date:  1993-12

Review 3.  Spontaneous intracerebral haemorrhage.

Authors:  A D Mendelow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-03       Impact factor: 10.154

4.  Frameless stereotactic aspiration and thrombolysis of deep intracerebral hemorrhage is associated with reduction of hemorrhage volume and neurological improvement.

Authors:  Paul Vespa; David McArthur; Chad Miller; Kristine O'Phelan; John Frazee; Chelsea Kidwell; Jeffery Saver; Sidney Starkman; Neil Martin
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

5.  [Recommendations of the European Stroke Initiative for the diagnosis and treatment of spontaneous intracerebral haemorrhage].

Authors:  S Külkens; P Ringleb; J Diedler; W Hacke; T Steiner
Journal:  Nervenarzt       Date:  2006-08       Impact factor: 1.214

6.  Frameless stereotactic aspiration and thrombolysis of spontaneous intracerebral hemorrhage.

Authors:  Ryan J Barrett; Rahat Hussain; William M Coplin; Samera Berry; Penelope M Keyl; Daniel F Hanley; Robert R Johnson; J Ricardo Carhuapoma
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

7.  Application of transcranial Doppler sonography in surgical aspects of hypertensive putaminal haemorrhage.

Authors:  E J Lee; C C Chio; H J Lin; L H Yang; H H Chen
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

8.  Proteasome Inhibitor Reduces Astrocytic iNOS Expression and Functional Deficit after Experimental Intracerebral Hemorrhage in Rats.

Authors:  Fahmi M Al-Senani; Xiurong Zhao; James C Grotta; Ali Shirzadi; Roger Strong; Jaroslaw Aronowski
Journal:  Transl Stroke Res       Date:  2011-10-19       Impact factor: 6.829

9.  Intracerebral hemorrhage: clinical overview and pathophysiologic concepts.

Authors:  Fred Rincon; Stephan A Mayer
Journal:  Transl Stroke Res       Date:  2012-04-21       Impact factor: 6.829

10.  Prognostic factors in patients with intracerebral haematoma.

Authors:  C L Franke; J C van Swieten; A Algra; J van Gijn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-08       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.